Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 567-575

  Ma, Brigette B Y ^a,e   Lui, Vivian W Y ^b   Hui, Connie W C ^a   Lau, Cecilia P Y ^a   Wong, Chi Hang ^a   Hui, Edwin P ^a   Ng, Margaret H ^a   Tsao, S W ^c   Li, Yan ^d   Chan, Anthony T C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d MERCK RESEARCH LABORATORIES   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AKT; MAPK; MK 2206; Nasopharyngeal cancer

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CISPLATIN; GLYCOGEN SYNTHASE KINASE 3; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN BAD; PROTEIN KINASE B; S6 KINASE; TRANSCRIPTION FACTOR FKHR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G0 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; NASOPHARYNX CARCINOMA; PIK3CA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NASOPHARYNGEAL NEOPLASMS; PACLITAXEL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84879106545     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9896-5     Document Type: Article

References (29)

1. Parkin DM, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
2. Ma BB, Hui EP, Chan AT (2008) Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci 99(7):1311-1318
3. Hui AB, Lo KW, Teo PM, To KF, Huang DP (2002) Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol 20(3):467-473
4. Or YY, Hui AB, To KF, Lam CN, Lo KW (2006) PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer 118(4):1065-1067
5. Morrison JA, Pathmanathan R, Raab-Traub N (2004) Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 64(15):5251-5260
6. Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF (2008) Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep 19(2):319-328
7. Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Chan AT (2010) The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs 28(4):413-420
8. Xu X, Yang H, Huo X (2004) Expression and significance of PTEN in nasopharyngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi 18(11):658-659
9. Chou CC, Chou MJ, Tzen CY (2008) PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol 26(3):322-326
10. Mainou BA, Raab-Traub N (2006) LMP1 strain variants: biological and molecular properties. J Virol 80(13):6458-6468
11. Shair KH, Schnegg CI, Raab-Traub N (2008) EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res 68(17):6997-7005
12. Mei YP, Zhou JM, Wang Y, Huang H, Deng R, Feng GK, Zeng YX, Zhu XF (2007) Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 6(11):1379-1385
13. Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X, Zhou L, Liao JJ, Keihack H, Yan L, Rubin EH, Yang JM (2011) MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 11(1):154-164
14. Knowles JA, Golden B, Yan L, Carroll WR, Helman EE, Rosenthal EL (2012) Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma. Laryngoscope 121(11):2359-2365
15. Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M (2012) The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab 96(4):E577-E585
16. Or YY, Hui AB, Tam KY, Huang DP, Lo KW (2005) Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. Int J Oncol 26(1):49-56
17. Lo AK, Lo KW, Tsao SW, Wong HL, Hui JW, To KF, Hayward DS, Chui YL, Lau YL, Takada K, Huang DP (2006) Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8(3):173-180
18. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9):3065-3074
19. Ma BB, Lui VW, Cheung CS, Lau CP, Ho K, Hui EP, Tsui SK, Ng MH, Cheng SH, Ng PK, Tsao SW, Chan AT (2012) Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. Invest New Drugs. [Epub ahead of print]
20. Ma BB, Lui VW, Poon FF, Wong SC, To KF, Wong E, Chen H, Lo KW, Tao Q, Chan AT, Ng MH, Cheng SH (2009) Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs 28(3):326-333
21. O'Reilly KE, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3):1500-1508
22. Ma B, Lui VW, Ho K, Lau CPY, Ng M, Cheng SH, Tsang CM, Tsao SW, Shi M, Hui EP, Chan ATC (2010) Preclinical evaluation of the dual PI3K-mTOR inhibitor BEZ235 in nasopharyngeal carcinoma cell lines. In Proc Am Assoc Cancer Res Meeting, Chicago. Abstract 1638
23. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW (2012) First-in-man clinical trial of the oral Pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688-4695
24. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G (2009) Mutations in the phosphatidylinositol-3- kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69(1):143-150
25. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12):1351-1356
26. Liu R, Liu D, Xing M (2012) The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab 97(2):E173-E182
27. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H (2011) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956-1967
28. Li Z, Yan S, Attayan N, Ramalingam S, Thiele CJ (2011) Combination of an allosteric Akt inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in Neuroblastoma. Clin Cancer Res 18(13):3603-3615
29. Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X (2007) Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer 120(9):1891-1898